HIV Integrase Inhibitor Synthesis via Segmented Crystal Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for synthesizing HIV integrase inhibitors, such as dolutegravir and cabotegravir, are not fully optimized, lacking a comprehensive and efficient method for preparing specific intermediates and final compounds with desired chemical structures and crystal forms.
Innovation Solution
A process involving the reaction of a compound with a hydroxyl protecting group and another specific compound, followed by conversion to form a compound with a defined powder X-ray diffraction spectrum, allowing for the production of HIV integrase inhibitors like dolutegravir, cabotegravir, and their intermediates, including specific crystal forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional processes are used for synthesizing HIV integrase inhibitors, then existing methods can produce the compounds, but the processes lack optimization and do not provide efficient preparation of specific intermediates with desired crystal forms
Solution Approach 1:
The synthesis process is divided into distinct segments: first forming the core polycyclic structure, then introducing the carbamoylpyridone moiety, and finally obtaining specific crystal forms. This segmentation allows each step to be optimized independently for both efficiency and precision.
Solution Approach 2:
The patent performs preliminary actions by establishing optimized reaction conditions and intermediate structures before final compound formation. Specific intermediates with defined structures are prepared in advance to ensure the final product achieves desired crystal forms and purity.
2Quantity of substance
If existing synthesis methods are applied, then compounds can be produced, but yield and purity are not optimized
Solution Approach 1:
The patent optimizes reaction parameters including temperature, solvent selection, reaction time, and stoichiometry to simultaneously maximize yield and purity. Specific parameter ranges are identified that provide both high conversion and clean reaction profiles.
Solution Approach 2:
The patent employs specific intermediate compounds with defined structures that act as mediators in the synthesis pathway. These intermediates are designed to facilitate high-yield transformations while maintaining purity through controlled reaction mechanisms.
3Productivity
If comprehensive optimization is implemented, then efficient production is achieved, but process complexity increases
Solution Approach 1:
The patent develops a universal synthesis platform that can produce multiple HIV integrase inhibitors (dolutegravir, cabotegravir, and analogs) using the same optimized methodology. This multi-functional approach achieves comprehensive optimization without proportionally increasing complexity.
Solution Approach 2:
By establishing optimized parameter ranges and conditions, the patent creates a robust process that maintains high efficiency while reducing the need for complex process controls. The optimized parameters provide inherent process stability.
Data Source
AI summary
The present invention provides compound of formula (XVII), wherein P is hydroxyl protecting group; R2 and R3 are independently lower alkyl or R2 and R3 can be alkyl and joined to form a 5-, 6- or 7-membered ring; R4 is lower alkyl, and process for its preparation.